AU2003287443A1 - Compositions and methods for pain reduction - Google Patents

Compositions and methods for pain reduction

Info

Publication number
AU2003287443A1
AU2003287443A1 AU2003287443A AU2003287443A AU2003287443A1 AU 2003287443 A1 AU2003287443 A1 AU 2003287443A1 AU 2003287443 A AU2003287443 A AU 2003287443A AU 2003287443 A AU2003287443 A AU 2003287443A AU 2003287443 A1 AU2003287443 A1 AU 2003287443A1
Authority
AU
Australia
Prior art keywords
compositions
methods
pain reduction
pain
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287443A
Other versions
AU2003287443A8 (en
Inventor
James Frederick Harrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Publication of AU2003287443A1 publication Critical patent/AU2003287443A1/en
Publication of AU2003287443A8 publication Critical patent/AU2003287443A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003287443A 2002-10-30 2003-10-30 Compositions and methods for pain reduction Abandoned AU2003287443A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42222402P 2002-10-30 2002-10-30
US60/422,224 2002-10-30
US10/695,680 US20040138204A1 (en) 2002-10-30 2003-10-29 Compositions and methods for pain reduction
US10/695,680 2003-10-29
PCT/US2003/034836 WO2004039247A2 (en) 2002-10-30 2003-10-30 Compositions and methods for pain reduction

Publications (2)

Publication Number Publication Date
AU2003287443A1 true AU2003287443A1 (en) 2004-05-25
AU2003287443A8 AU2003287443A8 (en) 2004-05-25

Family

ID=32233483

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287443A Abandoned AU2003287443A1 (en) 2002-10-30 2003-10-30 Compositions and methods for pain reduction

Country Status (6)

Country Link
US (1) US20040138204A1 (en)
EP (1) EP1581233A4 (en)
JP (1) JP2006513998A (en)
AU (1) AU2003287443A1 (en)
CA (1) CA2504647A1 (en)
WO (1) WO2004039247A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TWI475995B (en) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
KR20100080597A (en) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
EA019085B1 (en) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CN101861316B (en) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP2012503011A (en) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド Immunotherapy of chronic hepatitis C virus infection
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
DK2430022T3 (en) 2009-05-12 2013-12-02 Janssen Pharmaceuticals Inc 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use in the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (en) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PL2649069T3 (en) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
GB201311984D0 (en) 2013-07-04 2013-08-21 Univ Cardiff Methods and compounds for preventing or treating osteoarthritis
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
KR20200036063A (en) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EA202192105A3 (en) 2014-02-04 2022-02-28 Янссен Фармацевтика Нв COMBINATIONS CONTAINING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF THE METABOTROPIC GLUTAMATERGIC RECEPTOR 2 SUBTYPE AND THEIR USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039682A (en) * 1976-03-29 1977-08-02 Baxter Travenol Laboratories, Inc. Method and composition for relief of back pain
WO1998019674A2 (en) * 1996-11-05 1998-05-14 Head Explorer Aps A method for treating tension-type headache
GB9821503D0 (en) * 1998-10-02 1998-11-25 Novartis Ag Organic compounds
GB9908175D0 (en) * 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US6812211B2 (en) * 2002-03-19 2004-11-02 Michael Andrew Slivka Method for nonsurgical treatment of the intervertebral disc and kit therefor

Also Published As

Publication number Publication date
EP1581233A2 (en) 2005-10-05
WO2004039247A3 (en) 2005-03-31
EP1581233A4 (en) 2009-10-28
WO2004039247A2 (en) 2004-05-13
JP2006513998A (en) 2006-04-27
AU2003287443A8 (en) 2004-05-25
US20040138204A1 (en) 2004-07-15
CA2504647A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003287443A1 (en) Compositions and methods for pain reduction
AU2003267644A1 (en) Dental compositions and methods
AU2003266058A1 (en) Antimicrobial composition and method for use
AU2003259735A1 (en) Small-mer compositions and methods of use
IL165279A0 (en) Novel methods and compositions for alleviating pain
AU2003243531A1 (en) Fermentation methods and compositions
WO2003073826A8 (en) Novel compositions and methods for cancer
AU2003226094A1 (en) Compounds and methods
AU2003256805A1 (en) Compounds compositions and methods
AU2003271944A1 (en) Methods for making water treatment compositions and compositions thereof
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003284275A1 (en) Effervescent compositions comprising bisphosphonates and methods related thereto
AU2003297573A1 (en) Compositions and methods for treating transplants
AU2003232044A1 (en) Composition and method for dermatological treatment
EP1576109A3 (en) Methods and compositions for categorizing patients
AU2003295574A1 (en) Method and compositions for temporarily incapaciting subjets
AU2003275433A1 (en) Compositions and methods for treating pain
AU2003282593A1 (en) Polyphenolamine composition and method of use
AU2003263962A1 (en) Tissue compositions and methods for producing same
AU2003275240A1 (en) Methods and compositions for soluble cpg15
AU2003275069A1 (en) Compositions and methods for preventing infection
AU2003303948A1 (en) Compositions and methods for preventing infection
AU2003268078A1 (en) Levothyroxine compositions and methods
AU2003240446A1 (en) Use of mob-5 in pain
AU2003245524A1 (en) Cryosurgery compositions and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase